Preclinical Evaluation of In Vitro and In Vivo Antiviral Activities of KCT-01, a New Herbal Formula against Hepatitis B Virus

Figure 1

Analysis of in vitro cell cytotoxicity of KCT-01 on HepG2 and HepG2.2.15 cells. (a-b) HepG2 and HepG2.2.15 cells were treated with increasing doses of KCT-01 for 24 h (a) or 48 h (b). Cell viability was determined by MTT assays. Error bars represent standard deviations from triplicated samples.

(a)

(b)